An interventional study of Artemis + Medical Management and Best Medical Management Alone (MM) in Cerebral Hemorrhage, Brain Hemorrhage and Cerebral Parenchymal Hemorrhage, sponsored by Penumbra Inc.. Completed at 33 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Penumbra Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Cerebral Hemorrhage with a site in United States — 31 open to participants now, 42 under way, 6 of them phase 3. Cerebral Hemorrhage · United States.
Among the 109 studies in Cerebral Hemorrhage with a site in United States, this one is the 21st largest by enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2018, is one of 25 with no phase, and was the 51st registered.
457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.
Browse Cerebral Hemorrhage studies →31 of the 109 studies in Cerebral Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18+
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
Emory University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–80
Massachusetts General Hospital · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Cerebral Hemorrhage studies recruiting now, 58 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 24 · Phase 3 10 · Phase 4 3
First in 1993; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 236 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 60 across the 71 interventional studies, 245 across the 38 observational. Of the 61 that completed or were terminated, 28 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 109 have an industry lead sponsor. The 10 most frequent:
Penumbra Inc. is the lead sponsor of 33 studies on the registry; 4 are open to participants now.
Penumbra Inc. has 3 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
12 of the studies in Cerebral Hemorrhage with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT05020535Johns Hopkins UniversityBiomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) | 2026-11-30 |
| NCT06632587Thomas Jefferson UniversityTiming Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes | 2026-12-01 |
| NCT06725108University of ChicagoHemodynamic ABI Monitor | 2026-12-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 109 studies in Cerebral Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Imaging
Coagulation Issues
Patient Factors
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
Device: Artemis + Medical Management
Best medical management alone per standard of care at treating institution
Other: Best Medical Management Alone (MM)
Subject will receive best MM in addition to the MIS procedure with Artemis.
Also known as: MIS + MM
Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
Also known as: MM, Control
Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS)
Modified Rankin scale measures degree of disability or functional impairment on a scale of 0 (no symptoms) to 5 (severe disability), 6 (expired), where higher scores mean a worse outcome
Time frame: 180 days
Rate of Mortality
Time frame: 30 days
Functional Outcomes Measured Via Utility Weighted Modified Rankin Score (mRS)
The utility-weighted modified Rankin Score (utility-weighted mRS) is a functional outcome measure that quantifies global disability. It is derived from the Ordinal Modified Rankin Scale (mRS), which assesses the degree of disability or functional impairment on a scale. The underlying Modified Rankin Scale categories range from 0 to 6, where: * 0 = No symptoms (best outcome) * 6 = Death (worst outcome) These categorical mRS values are converted to utility weights and the resulting the utility-weighted mRS produces a continuous score ranging from 0.00 to 1.00, where: * 0.00 represents the worst functional outcome (equivalent to severe disability or death) * 1.00 represents the best functional outcome (no symptoms and full independence) Higher scores indicate better functional outcomes. Lower scores indicate worse functional outcomes.
Time frame: 180 days
Functional Outcomes Measured Via Modified Ordinal Rankin Score (mRS)
Modified Rankin scale measures degree of disability or functional impairment on a scale of 0 (no symptoms) to 5 (severe disability), 6 (expired), where higher scores mean a worse outcome
Time frame: 365 days
Quality of Life Assessed Via Stroke Impact Scale
The Stroke Impact Scale measures mobility and activities of daily living by assessing ability to perform specific physical tasks using a 5-point scale that ranges from 1 (could not do it at all) to 5 (not difficult at all). The individual scores are converted to a scale of 0 (no recovery) -100 (full recovery) to represent level of recovery, where a higher score means better outcome.
Time frame: 180 and 365 days
VAS Quality of Life Assessed Via EQ-5D-5L
The EQ-5D-5L (EuroQol 5 Dimension 5 Level) is a self assessment on activities of daily living using a visual analog scale (VAS) where current health is rated on a scale of 0 to 100 where 0 is the worst imaginable health and 100 is the best imaginable health.
Time frame: 180 and 365 days
Length of Hospital Stay
Time frame: Admission to hospital discharge (up to one year)
Length of ICU
Time frame: # of days from admission (up to one year)
Length of Procedure
Time frame: Time from initial sheath placement to final sheath removal
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 3
(0 no symptoms - 3 moderate disability)
Time frame: 180 days
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 2
mRS 0 no symptoms - 2 slight disability
Time frame: 180 days
| Milestone | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Started | 154 | 82 |
| Completed | 139 | 70 |
| Not completed | 15 | 12 |
Modified Rankin scale measures degree of disability or functional impairment on a scale of 0 (no symptoms) to 5 (severe disability), 6 (expired), where higher scores mean a worse outcome
| Participants | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Missing mRS value | 32 | 20 |
| mRS 0 | 4 | 2 |
| mRS 1 | 5 | 1 |
| mRS 2 | 11 | 8 |
| mRS 3 | 28 | 14 |
| mRS 4 | 38 | 13 |
| mRS 5 | 14 | 10 |
| mRS 6 | 22 | 14 |
| Participants | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Rate of Mortality | 11 | 8 |
The utility-weighted modified Rankin Score (utility-weighted mRS) is a functional outcome measure that quantifies global disability. It is derived from the Ordinal Modified Rankin Scale (mRS), which assesses the degree of disability or functional impairment on a scale. The underlying Modified Rankin Scale categories range from 0 to 6, where: * 0 = No symptoms (best outcome) * 6 = Death (worst outcome) These categorical mRS values are converted to utility weights and the resulting the utility-weighted mRS produces a continuous score ranging from 0.00 to 1.00, where: * 0.00 represents the worst functional outcome (equivalent to severe disability or death) * 1.00 represents the best functional outcome (no symptoms and full independence) Higher scores indicate better functional outcomes. Lower scores indicate worse functional outcomes.
| score on a scale | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Functional Outcomes Measured Via Utility Weighted Modified Rankin Score (mRS) | 0.41 ± 0.314 | 0.38 ± 0.318 |
Modified Rankin scale measures degree of disability or functional impairment on a scale of 0 (no symptoms) to 5 (severe disability), 6 (expired), where higher scores mean a worse outcome
| Participants | Artemis + Medical Management (MIS) All Participants All Participants | Best Medical Management Alone (MM) |
|---|---|---|
| Missing mRS value | 15 | 12 |
| mRS 0 | 4 | 0 |
| mRS 1 | 15 | 6 |
| mRS 2 | 11 | 15 |
| mRS 3 | 31 | 12 |
| mRS 4 | 45 | 14 |
| mRS 5 | 6 | 7 |
| mRS 6 | 27 | 16 |
The Stroke Impact Scale measures mobility and activities of daily living by assessing ability to perform specific physical tasks using a 5-point scale that ranges from 1 (could not do it at all) to 5 (not difficult at all). The individual scores are converted to a scale of 0 (no recovery) -100 (full recovery) to represent level of recovery, where a higher score means better outcome.
| score on a scale | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Mobility (180 days) | 54.3 ± 33.67 | 53.9 ± 34.19 |
| Activities of Daily Living (180 days) | 53.4 ± 31.89 | 53.8 ± 32.59 |
| Mobility (365 days) | 55.0 ± 32.51 | 58.4 ± 33.99 |
| Activities of Daily Living (365 days) | 55.8 ± 30.66 | 56.2 ± 33.40 |
The EQ-5D-5L (EuroQol 5 Dimension 5 Level) is a self assessment on activities of daily living using a visual analog scale (VAS) where current health is rated on a scale of 0 to 100 where 0 is the worst imaginable health and 100 is the best imaginable health.
| score on a scale | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| EQ-5D-5L-180 days | 61.6 ± 23.41 | 62.4 ± 22.82 |
| EQ-5D-5L-365 days | 62.7 ± 22.42 | 66.0 ± 22.03 |
| days | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Length of Hospital Stay | 18.8 ± 17.81 | 20.6 ± 12.75 |
| days | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Length of ICU | 7.6 ± 6.51 | 9.2 ± 8.39 |
| minutes | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Length of Procedure | 41 ± 29.81 | 34 ± NA |
(0 no symptoms - 3 moderate disability)
| Participants | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 3 | 57 | 32 |
mRS 0 no symptoms - 2 slight disability
| Participants | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 2 | 26 | 14 |
Collected over Within 365 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Artemis + Medical Management (MIS) | 27/154 (17.5%) | 89/154 (57.8%) | 107/154 (69.5%) |
| Best Medical Management Alone (MM) | 16/82 (19.5%) | 60/82 (73.2%) | 56/82 (68.3%) |
| Event | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| Brain oedemaNervous system disorders | 4/154 | 10/82 |
| Cerebral haemorrhageNervous system disorders | 17/154 | 3/82 |
| SepsisInfections and infestations | 4/154 | 9/82 |
| Deep vein thrombosisVascular disorders | 9/154 | 9/82 |
| PneumoniaInfections and infestations | 4/154 | 7/82 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 6/154 | 6/82 |
| Ischaemic strokeNervous system disorders | 3/154 | 4/82 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/154 | 4/82 |
| Haemorrhage intracranialNervous system disorders | 7/154 | 2/82 |
| SeizureNervous system disorders | 6/154 | 1/82 |
| Event | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) |
|---|---|---|
| TotalInfections and infestations | 41/154 | 20/82 |
| DysphagiaGastrointestinal disorders | 15/154 | 12/82 |
| Urinary tract infectionInfections and infestations | 17/154 | 7/82 |
| PneumoniaInfections and infestations | 16/154 | 7/82 |
| SeizureNervous system disorders | 12/154 | 7/82 |
| PyrexiaGeneral disorders | 13/154 | 6/82 |
| HypernatraemiaMetabolism and nutrition disorders | 4/154 | 6/82 |
| HypokalaemiaMetabolism and nutrition disorders | 8/154 | 5/82 |
| Urinary retentionRenal and urinary disorders | 8/154 | 1/82 |
| Deep vein thrombosisVascular disorders | 5/154 | 4/82 |
| Age, Continuous(Years) | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) | Total |
|---|---|---|---|
| Mean | 59.6 ± 11.71 | 59.2 ± 12.33 | 59.4 ± 11.90 |
| Sex: Female, Male(Participants) | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) | Total |
|---|---|---|---|
| Female | 55 | 32 | 87 |
| Male | 99 | 50 | 149 |
| Ethnicity (NIH/OMB)(Participants) | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 9 | 31 |
| Not Hispanic or Latino | 115 | 61 | 176 |
| Unknown or Not Reported | 17 | 12 | 29 |
| Race/Ethnicity, Customized(Participants) | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 12 | 11 | 23 |
| Black or African American | 23 | 14 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 102 | 45 | 147 |
| More Than One Race | 2 | 0 | 2 |
| Other | 3 | 1 | 4 |
| Unknown | 1 | 4 | 5 |
| Not Reported | 10 | 7 | 17 |
| Region of Enrollment(participants) | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) | Total |
|---|---|---|---|
| Canada | 2 | 1 | 3 |
| Austria | 0 | 1 | 1 |
| United States | 142 | 74 | 216 |
| Germany | 10 | 6 | 16 |
| BMI(kg/m2) | Artemis + Medical Management (MIS) | Best Medical Management Alone (MM) | Total |
|---|---|---|---|
| Mean | 30.4 ± 8.21 | 30.9 ± 7.28 | 30.6 ± 7.88 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Feb 2024, 72 months.
Results were first posted in Jan 2026, 1 year 11 months after primary completion.
Of 84 interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 72. This study's 72 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.